Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 ...
More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...
ATHENA study shows the cobas HPV Test advances the standard of care by providing valuable information on the risks associated with the genotypes which cause 70 percent of cervical cancer Results from ...
A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...
The Food and Drug Administration approved the Roche cobas HPV Test to detect human papilloma virus through the use of cervical cells collected for a Pap test and stored in SurePath Preservative Fluid.
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
(RTTNews) - Biopharmaceutical company Roche Holding AG (RHHBY), announced on Tuesday that its cobas HPV test for use on the cobas 6800/8800 Systems has been awarded the World Health Organization (WHO) ...
(HealthDay News) — The cobas human papillomavirus (HPV) test is an effective, one-test alternative to the current recommendation of screening with either a Pap test alone or a combination of the HPV ...
The U.S. Food and Drug Administration (FDA) has approved a human papillomavirus (HPV) DNA test for women 25 and older that can be used to determine whether these women should have additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results